María Isabel Martínez Fernández-rekin lankidetzan egindako argitalpenak (11)

2023

  1. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

    International journal of molecular sciences, Vol. 24, Núm. 4

  2. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

    Cancers, Vol. 15, Núm. 7

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

  2. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

    Science Advances, Vol. 8, Núm. 20

2021

  1. Fertility and breast cancer: A literature review of counseling, preservation options and outcomes

    Critical Reviews in Oncology/Hematology, Vol. 166

  2. Identification of a two-microrna signature in plasma as a novel biomarker for very early diagnosis of breast cancer

    Cancers, Vol. 13, Núm. 11

  3. Oral selective estrogen receptor degraders (Serds) as a novel breast cancer therapy: Present and future from a clinical perspective

    International Journal of Molecular Sciences, Vol. 22, Núm. 15

  4. Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation

    ESMO open, Vol. 6, Núm. 3, pp. 100148

2020

  1. miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker

    Breast Cancer: Basic and Clinical Research, Vol. 14

2019

  1. Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator

    Breast Cancer: Basic and Clinical Research, Vol. 13

2014

  1. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822